A Phase I Study of Intravitreal Vascular Endothelial Growth Factor Trap-Eye in Patients with Neovascular Age-Related Macular Degeneration

Ophthalmology

Volumn 116, Issue 11, 2009, Pages

  Nguyen, Quan Dong ^a   Shah, Syed Mahmood ^a   Browning, David J ^b   Hudson, Henry ^c   Sonkin, Peter ^d   Hariprasad, Seenu M ^e   Kaiser, Peter ^f   Slakter, Jason S ^g   Haller, Julia ^a   Do, Diana V ^a   Mieler, William F ^e   Chu, Karen ^h   Yang, Ke ^h   Ingerman, Avner ^h   Vitti, Robert L ^h   Berliner, Alyson J ^h   Cedarbaum, Jesse M ^h   Campochiaro, Peter A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Charlotte Eye Ear   (United States)

^c Retina Centers PC   (United States)

^d Retina Vitreous Associates   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g VITREOUS RETINA MACULA CONSULTANTS OF NEW YORK   (United States)

^h REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EYE EXAMINATION; EYE INFLAMMATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; LABORATORY TEST; LOW DRUG DOSE; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RETINA FOVEA; RETINA INJURY; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; VITAL SIGN;

EID: 70350757650     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2009.04.030     Document Type: Article

References (13)

1. Klein R., Klein B.E., Linton K.P., and DeMets D.L. The Beaver Dam Eye Study: the relation of age-related maculopathy to smoking. Am J Epidemiol 137 (1993) 190-200
2. Kwak N., Okamoto N., Wood J.M., and Campochiaro P.A. VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci 41 (2000) 3158-3164
3. Kryzstolik M.G., Afshari M.A., Adamis A.P., et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 120 (2002) 338-346
4. Gragoudas E.S., Adamis A.P., Cunningham Jr. E.T., et al., VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 (2004) 2805-2816
5. Rosenfeld P.J., Brown D.M., Heier J.S., et al., MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1419-1431
6. Brown D.M., Kaiser P.K., Michels M., et al., ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1432-1444
7. Carmeliet P., Moons L., Luttun A., et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7 (2001) 575-583
8. Holash J., Davis S., Papadoupoulos N., et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 99 (2002) 11393-11398
9. Nguyen Q.D., Shah S.M., Hafiz G., et al., CLEAR-AMD 1 Study Group. A phase 1 trial of intravenously administered vascular endothelial growth factor Trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 113 (2006) 1522-1532
10. Saishin Y., Saishin Y., Takahashi K., et al. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol 195 (2003) 241-248
11. Zimmer E., Christian B.J., Miller P.E., et al. Safety evaluation of intravitreal administration of VEGF trap in Cynomolgus monkeys for 13 weeks. Invest Ophthalmol Vis Sci 47 (2006) E-Abstract 1751
12. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: five year results from randomized clinical trials. Arch Ophthalmol 109 (1991) 1109-1114
13. Nguyen Q.D., Shah S.M., Hafiz G., et al. Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age-related macular degeneration. Am J Ophthalmol 145 (2008) 257-266